Pharmacotherapy of pathological gambling

Psychiatric Annals

Volumn 32, Issue 3, 2002, Pages

  Grant, Jon E ^a   Kim, Suck Won ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; FLUVOXAMINE; LITHIUM; LITHIUM CARBONATE; NALMEFENE; NALTREXONE; OPIATE ANTAGONIST; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADDICTION; ANXIETY DISORDER; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; EUPHORIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; IMPULSE CONTROL DISORDER; LIVER FUNCTION TEST; LIVER TOXICITY; LONELINESS; NAUSEA; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGICAL GAMBLING; PRACTICE GUIDELINE; PSYCHOANALYTIC THEORY; PSYCHOTHERAPY; REMISSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0242382815     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-20020301-08     Document Type: Review

References (29)

1. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health. 1999;89:1369-1376.
2. Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47:813-817.
3. Blanco-Jerez C. A long-term, double-blind, placebo-controlled study of fluvoxamine for pathological gambling. Presented at: 152nd Annual Meeting of the American Psychiatric Association; May 16-21, 1999; Washington, DC.
4. Kim SW, Grant JE, Shin YC, Toth JA, Adson DE, Zaninelli RM. A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling disorder. J Clin Psychiatry. In press.
5. Kim SW, Grant JE, Adson DE, Shin YC. A double-blind, placebo-controlled study of naltrexone in the treatment of pathological gambling disorder. Biol Psychiatry. 2001;49:914-921.
6. Hollander E, Frenkel M, DeCaria C, Trungold S, Stein DJ. Treatment of pathological gambling with clomipramine. Am J Psychiatry. 1992;149:710-711. Letter.
7. Haller R, Hinterhuber H. Treatment of pathological gambling with carbamazepine. Pharmacopsychiatry 1994;27:129.
8. Hollander E, DeCaria CM, Mari E, et al. Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry. 1998;155:1781-1783.
9. Zimmerman M, Breen R. An open-label study of citalopram in the treatment of pathological gambling. Presented at: 11th International Conference on Gambling and Risk Taking; June 17-21, 2000; Las Vegas, Nev.
10. De la Gandara JJ. Fluoxetine: open-trial in pathological gambling. Presented at: 152 Annual Meeting of the American Psychiatric Association; May 16-21, 1999; Washington, DC.
11. Moskowitz JA. Lithium and lady luck: use of lithium carbonate in compulsive gambling. NY State J Med. 1980;80:785-788.
12. Crockford DN, el-Guebaly N. Naltrexone in the treatment of pathological gambling and alcohol dependence. Can J Psychiatry. 1998;43:86. Letter.
13. Oldham JM, Hollander E, Skodol AE, eds. Impulsivity and Compulsivity. Washington, DC: American Psychiatric Press; 1996.
14. Bohn MJ, Barton BA, Barron KE. Psychometric properties and validity of the obsessive-compulsive drinking scale. Alcohol Clin Exp Res. 1996;20:817-823.
15. Thoren P, Asberg M, Crohnholm B, Jornestedt L, Trachman L. Clomipramine treatment of obsessive compulsive disorder, I: a controlled trial. Arch Gen Psychiatry. 1980;37:1281-1285.
16. Insel T, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnolia M. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983;40:605-612.
17. Flament MF, Rapoport JL, Berg CJ. Clomipramine treatment of childhood obsessive-compulsive disorder: a double blind controlled study. Arch Gen Psychiatry. 1987;42:977-983.
18. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res. 1985;14:83-91.
19. Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am J Psychiatry. 1985;142:572-576.
20. Sutherland G, Stapleton JA, Russell MAH, Feyerabend C. Naltrexone, smoking behaviour, and cigarette withdrawal. Psychopharmacology (Berl). 1995;120:418-425.
21. Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry. 1987;22:35-42.
22. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
23. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54:737-742.
24. McElroy SL, Pope HG Jr, Keck PE, Hudson JI, Phillips KA, Strakowski SM. Are impulse-control disorders related to bipolar disorder? Compr Psychiatry. 1996;37:229-240.
25. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on a possible naltrexone and nonsteroidal analgesics interaction. J Clin Psychopharmacol. 2001;21:632-634. Letter.
26. Knopman DS, Hartman M. Cognitive effects of high-dose naltrexone in patients with probable Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1986;49:1321-1322. Letter.
27. Volpicelli JR, Clay KL, Watson NT, O'Brien CP. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry. 1995;7(suppl):39-44.
28. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719-724.
29. Salvato FR, Mason BJ. Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject. Alcohol Clin Exp Res. 1994;18:1187-1189.